Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endocrine pancreas

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Endocrine pancreas. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2008-007348-32 Sponsor Protocol Number: CSOM230D2203 Start Date*: 2009-05-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin
    Medical condition: The following tumors are included: 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma, 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004904-35 Sponsor Protocol Number: Protocol2-55-52030-726 Start Date*: 2006-08-14
    Sponsor Name:IPSEN PHARMA S.A.S.
    Full Title: Phase III, randomised, double-blind, stratified comparative, placebo controlled, parallel group, multicentre study to assess the effect of deep subcutaneous injections of lanreotide Autogel 120 mg ...
    Medical condition: Non functioning entero-pancreatic tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Completed) CZ (Completed) GR (Completed) SE (Completed) DE (Completed) AT (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000069-34 Sponsor Protocol Number: PAMORA_2020_RAP Start Date*: 2021-11-19
    Sponsor Name:Mech-Sense, Aalborg University Hospital
    Full Title: Effects of a peripherally acting μ-opioid receptor antagonist on recurrent acute pancreatitis: An investigator-initiated, randomized, placebo-controlled, double-blind clinical trial
    Medical condition: Recurrent acute pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10033647 Pancreatitis acute PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005028-13 Sponsor Protocol Number: MK-6482-015 Start Date*: 2021-07-19
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendoc...
    Medical condition: Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumor or von Hippel-Lindau (VHL) Disease-Associated Tumors or Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors with HIF...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10034876 Pheochromocytoma LLT
    20.0 100000004864 10073860 Paraganglioma LLT
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    20.0 100000004864 10062427 Gastrointestinal stromal tumor LLT
    21.1 100000004864 10065147 Malignant solid tumor LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10047716 Von Hippel-Lindau disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002445-31 Sponsor Protocol Number: SIMBA-16 Start Date*: 2017-01-20
    Sponsor Name:Enrique de Madaria
    Full Title: SIMBA trial: Simvastatin in the Prevention of Recurrent Acute Pancreatitis, a Triple Blind Randomized Controlled Trial
    Medical condition: Recurrent acute pancreatitis (RAP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10033647 Pancreatitis acute PT
    20.0 10017947 - Gastrointestinal disorders 10033657 Pancreatitis relapsing PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000619-10 Sponsor Protocol Number: RUNMC-EX-BCM-2012 Start Date*: 2012-07-24
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Clinical proof-of-principle of the determination of the beta cell mass in vivo by SPECT imaging with the 111In-labeled GLP-1 analogue DTPA-[K40]-Exendin 4
    Medical condition: patients with long-standing type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    14.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    14.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005599-27 Sponsor Protocol Number: ABR51980 Start Date*: 2016-12-07
    Sponsor Name:Radboud University Medical Center Nijmegen
    Full Title: Visualizing beta cells in morbid obese patients with T2D before and after bariatric surgery (NL51980.091.15)
    Medical condition: Diabetes Type 2, bariatric surgery, morbid obesitas
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    19.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    19.0 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000592-17 Sponsor Protocol Number: MODY-TREAT Start Date*: 2012-08-03
    Sponsor Name:Signe H. Østoft, Diabetes Research Division
    Full Title: The effects of GLP-1 in Maturity- onset diabetes of the young (MODY)
    Medical condition: 'Maturity onset diabetes of the young', also called 'Hepatocyte nuclear factor 1-alfa daiabetes'. It is a monogenic form of inherited diabetes.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10026948 Maturity-onset diabetes of the young LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000369-54 Sponsor Protocol Number: 60725 Start Date*: 2018-06-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Intra-arterial Lutetium-177- dotatate for treatment of patients with neuroendocrine tumor liver metastases
    Medical condition: Patients with neuro-endocrine tumors with liver metastases with an indication for treatment with lutetium-177-dotatate
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001467-39 Sponsor Protocol Number: GETNE1509 Start Date*: 2015-07-24
    Sponsor Name:GETNE (Grupo Español de Tumores Neuroendocrinos)
    Full Title: A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin.
    Medical condition: Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent (cohor...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002328-40 Sponsor Protocol Number: HHSC/005 Start Date*: 2007-05-18
    Sponsor Name:Imperial College London
    Full Title: A phase I safety and tolerability study of infusing the autologous progeny of an adult CD34+ subset into patients with type I diabetes mellitus and a successful renal transplant.
    Medical condition: Diabetes mellitus type 1 and succesful renal transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012638 Diabetes with renal manifestations LLT
    9.1 10038533 Renal transplant LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004317-90 Sponsor Protocol Number: NL51058.091.14 Start Date*: 2015-02-25
    Sponsor Name:Radboud University Medical Center Nijmegen
    Full Title: Visualizing beta cells in patients with remission of T2DM after bariatric surgery
    Medical condition: Patients with Type 2 Diabetes, with or without remission after bariatric surgery
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    17.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    17.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004727-37 Sponsor Protocol Number: CAAA603A12101 Start Date*: 2019-02-18
    Sponsor Name:Advanced Accelerator Applications International SA
    Full Title: A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with...
    Medical condition: Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) DE (Completed) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-003006-33 Sponsor Protocol Number: RUNMC-GLP1-EX-GELO-2014 Start Date*: 2015-02-16
    Sponsor Name:Radboud University Medical Center
    Full Title: Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 uptake in the kidney
    Medical condition: The aim of this study is to reduce the kidney uptake during 111In-DTPA- exendin4 imaging, a promising and valuable tool for beta-cell mass imaging and quantification, which can be applied in patien...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    17.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    17.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    17.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004928-39 Sponsor Protocol Number: D-FR-01070-002 Start Date*: 2017-11-23
    Sponsor Name:Ipsen Pharma
    Full Title: A multicentre, randomised, dose-confirmation, factorial phase II study to evaluate the optimal dose of 68Ga-OPS202 as a PET imaging agent in subjects with gastroenteropancreatic neuroendocrine tumo...
    Medical condition: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Prematurely Ended) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001697-17 Sponsor Protocol Number: A-94-52030-268 Start Date*: 2014-05-23
    Sponsor Name:Ipsen Pharma GmbH
    Full Title: PHASE II, MULTICENTRE, OPEN LABEL STUDY TO EVALUATE THE EFFICACY OF THE COMBINATION OF LANREOTIDE AUTOGEL 120 MG AND TEMOZOLOMIDE IN PATIENTS WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRIN...
    Medical condition: metastatic functioning and non-functioning entero-pancreatic tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 04:55:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA